Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study
Margaret Gartland, Xuming Wang, Qilong Liao, Bo Li et autres
0 citationsHIV Medicine
Allan R. Tenorio
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
80Publications signalées
4386Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
HIV Research and TreatmentHIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHepatitis C virus researchHIV-related health complications and treatments
Publications récentes
TRAJETÓRIAS SOCIOECONÔMICAS E EDUCACIONAIS DE EGRESSOS DO ENSINO TÉCNICO CONCOMITANTE
Allan R. Tenorio, Nonato Assis de Miranda, Leandro Campi Prearo
0 citationsRevista ORG & DEMO
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Princy Kumar, Shannon Schrader, Shiven Chabria, Margaret Gartland et autres
0 citationsCarolina Digital Repository (University of North Carolina at Chapel Hill)
Fostemsavir resistance in clinical context: a narrative review
Jonathan Schapiro, Rolf Kaiser, Mark Krystal, Chris M. Parry et autres
1 citationTherapeutic Advances in Infectious Disease
Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study
Andrew Clark, Manyu Prakash, Shiven Chabria, Amy Pierce et autres
8 citationsOpen Forum Infectious Diseases
Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab
Margaret Gartland, Eugene L. Stewart, Nannan Zhou, Zhufang Li et autres
6 citationsAntiviral Research
The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate
David Wensel, Margaret Gartland, Jagadish Beloor, Kartika N. Shetty et autres
1 citationAntiviral Research
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study
Josep M. Llibre, Judith A. Aberg, Sharon Walmsley, Juan D. Vélez et autres
6 citationsFrontiers in Immunology
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Alftan Dyson, Judith A. Aberg, Jean‐Michel Molina, Isabel Cassetti et autres
0 citationsOpen Forum Infectious Diseases
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Judith A. Aberg, Bronagh Shepherd, Marcia Wang, José V. Madruga et autres
20 citationsInfectious Diseases and Therapy
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials
Kristian Reich, Marjolein de Bruin‐Weller, Mette Deleuran, Brian Calimlim et autres
16 citationsJournal of the European Academy of Dermatology and Venereology
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Kim Papp et autres
68 citationsJournal of Allergy and Clinical Immunology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.